Doing a deal with Organon is worth probably $2M. That's enough to run for another month or two and that wouldn't be worth the bother. There'd be nothing left.
I think Stoll needs to come up with a plan and tell us. It would be nice to hear that the orphan development idea is off the table. That happens (not focusing on Ampakines) and I'm selling.
Market Data 
Markets 
AI
